Can lesions of GPe correct HD deficits?

Experimental Neurology

Volumn 186, Issue 1, 2004, Pages 1-5

  Reiner, A ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT;

BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN FUNCTION; BRAIN INJURY; BRAIN NERVE CELL; BRAIN REGION; CORPUS STRIATUM; DISEASE COURSE; DISEASE MODEL; ELECTROPHYSIOLOGY; GLOBUS PALLIDUS; HUMAN; HUNTINGTON CHOREA; MOTOR CONTROL; MOTOR DYSFUNCTION; MOVEMENT (PHYSIOLOGY); NERVE CONDUCTION; NERVE EXCITABILITY; NERVE PROJECTION; NERVE TRACT; NONHUMAN; NOTE; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; SYMPTOM; TASK PERFORMANCE;

EID: 1242293853     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.expneurol.2003.11.002     Document Type: Note

References (49)

1. Albin R.L., Tagle D.A. Genetics and molecular biology of Huntington's disease. Trends Neurosci. 18:1995;11-14.
2. Albin R.L., Young A.B., Penney J.B. The functional anatomy of basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
3. Albin R.L., Reiner A., Anderson K.D., Penney J.B., Young A.B. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Ann. Neurol. 27:1990;357-365.
4. Albin R.L., Young A.B., Penney J.B. The functional anatomy of disorders of the basal ganglia. Trends Neurosci. 18:1995;63-64.
5. Alexander G.E., Crutcher M.D. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci. 13:1990;266-271.
6. Ayalon L., Doron R., Weiner I., Joel D. Amelioration of behavioral deficits in a rat model of Huntington's disease by an excitotoxic lesion to the globus pallidus. Exp. Neurol. 186:2004;46-58.
7. Beal M.F., Kowall N.W., Ellison D.W., Mazurek M.F., Swartz K.J., Martin J.B. Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature. 321:1986;168-171.
8. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science. 249:1990;1436-1438.
9. Brown L.L., Smith D.M., Goldbloom L.M. Organizing principles of cortical integration in the rat neostriatum: corticostriate map of the body surface is an ordered lattice of curved laminae and radial points. J. Comp. Neurol. 392:1998;468-488.
10. Chesselet M.F., Delfs J.M. Basal ganglia and movement disorders: an update. Trends Neurosci. 19:1996;417-422.
11. Cowan R.H., Wilson C.J. Spontaneous firing patterns and axonal projections of single corticostriatal neurons in the rat medial agranular cortex. J. Neurophysiol. 71:1994;17-32.
12. Crossman A.R. Primate models of dyskinesia: the experimental approach to the study of basal ganglia-related involuntary movement disorders. Neuroscience. 21:1987;1-40.
13. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 13:1990;281-285.
14. Deniau J.M., Chevalier G. Disinhibition as a basic process in the expression of striatal functions: II. The striato-nigral influence on thalamocortical cells of the ventromedial thalamic nucleus. Brain Res. 334:1985;227-233.
15. Donoghue J.P., Kitai S.T. A collateral pathway to the neostriatum from corticofugal neurons of the rat sensory-motor cortex: an intracellular HRP study. J. Comp. Neurol. 210:1981;1-13.
16. Figueredo-Cardenas G., Anderson K.D., Chen Q., Veenman C.L., Reiner A. Relative survival of striatal projection neurons and interneurons after intrastriatal injection of quinolinic acid in rats. Exp. Neurol. 129:1994;37-56.
17. Francois C., Yelnik J., Percheron G., Tande D. Calbindin D-28k as a marker for the associative territory of the striatum in macaque. Brain Res. 633:1994;331-336.
18. Furtado J.C., Mazurek M.F. Behavioral characterization of quinolinate-induced lesions of the medial striatum: relevance for Huntington's disease. Exp. Neurol. 138:1996;158-168.
19. Gasser T., Harding A.E. Huntington's disease and Sydenham's chorea. Brandt T., Caplan C., Dichgans J., Diener H.C., Kennard C. Neurological Disorders: Course and Treatment. 1996;797-802 Academic Press, New York.
20. Gerfen C.R. The neostriatal mosaic: multiple levels of compartmental organization in the basal ganglia. Annu. Rev. Neurosci. 15:1992;285-320.
21. Gerfen C.R., Wilson C.J. The basal ganglia. Swanson L.W., Bjorklund A., Hokfelt T. Handbook of Chemical Neuroanatomy. 1996;371-468 Elsevier Science, Amsterdam.
22. Graybiel A.M. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci. 13:1990;244-253.
23. Hauber W., Schmidt W.J. Discrete quinolinic acid lesions of the lateral but not of the medial caudate-putamen reversed haloperidol-induced catalepsy in rats. J. Neural Transm., Gen. Sect. 94:1993;103-114.
24. Hauber W., Lutz S., Münkle M. The effects of globus pallidus lesions on dopamine-dependent motor behavior in rats. Neuroscience. 86:1998;147-157.
25. Hoffer Z.S., Alloway K.D. Organization of corticostriatal projections from the vibrissal representations in the primary motor and somatosensory areas of rodents. J. Comp. Neurol. 439:2001;87-103.
26. Joel D. Open interconnected model of basal ganglia-thalamocortical circuitry and its relevance to the clinical syndrome of Huntington's disease. Mov. Disord. 16:2001;407-423.
27. Joel D., Weiner I. The organization of the basal ganglia-thalamocortical circuits: open interconnected rather than closed segregated. Neuroscience. 63:1994;363-379.
28. Joel D., Weiner I. The connections of the primate subthalamic nucleus: indirect pathways and the open-interconnected scheme of basal ganglia-thalamocortical circuitry. Brain Res. Rev. 23:1997;62-78.
29. Joel D., Ayalon L., Tarrasch R., Veenman L., Feldon J., Weiner I. Electrolytic lesion of globus pallidus ameliorates the behavioral and neurodegenerative effects of quinolinic acid lesion of the striatum: a potential novel treatment in a rat model of Huntington's disease. Brain Res. 787:1998;143-148.
30. Kawashima Y., Takahashi A., Hirato M., Ohye C. Stereotactic Vim-Vo-thalamotomy for choreatic movement disorder. Acta Neurochir. 52:1991;103-106.
31. Kita H., Kitai S.T. Efferent projections of the subthalamic nucleus in the rat: light and electron microscopic analysis with the PHA-L method. J. Comp. Neurol. 260:1987;435-452.
32. Levesque M., Gagnon S., Parent A., Descenes M. Axonal arborizations of corticostriatal and corticothalamic fibers arising from the second somatosensory area in the rat. Cereb. Cortex. 6:1996;759-770.
33. Marsden C.D. The mysterious motor functions of the basal ganglia: the Robert Wartenberg lecture. Neurology. 32:1982;514-539.
34. Marsden C.D., Obeso J.A. The functions of the basal ganglia and the paradox of stereotaxic surgery in Parkinson's disease. Brain. 117:1994;877-897.
35. Martin J.B., Gusella J.F. Huntington's disease. Pathogenesis and management. N. Engl. J. Med. 315:1986;1267-1276.
36. Page R.D., Sambrook M.A., Crossman A.R. Thalamotomy for the alleviation of levo-dopa-induced dyskinesia: experimental studies in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treated parkinsonian monkey. Neuroscience. 55:1993;147-165.
37. Paleacu D., Anca M., Giladi N. Olanzipine in Huntington's disease. Acta Neurol. Scand. 105:2002;441-444.
38. Penney J.B. Jr., Young A.B. Striatal inhomogeneities and basal ganglia function. Mov. Disord. 1:1986;3-15.
39. Penney J.B. Jr., Vonsattel J.P., MacDonald M.E., Gusella J.F., Myers R.H. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann. Neurol. 41:1997;689-692.
40. Pisa M., Cyr J. Regionally selective roles of the rat's striatum in modality-specific discrimination learning and forelimb reaching. Behav. Brain Res. 37:1990;281-292.
41. Reading P.J., Dunnett S.B., Robbins T.W. Dissociable roles of the ventral, medial and lateral striatum on the acquisition and performance of a complex visual stimulus-response habit. Behav. Brain Res. 45:1991;147-161.
42. Reiner A., Anderson K.D. The patterns of neurotransmitter and neuropeptide co-occurrence among striatal projection neurons: conclusions based on recent findings. Brain Res. Rev. 15:1990;251-265.
43. Reiner A., Albin R.L., Anderson K.D., D'Amato C.J., Penney J.B., Young A.B. Differential loss of striatal projection neurons in Huntington disease. Proc. Natl. Acad. Sci. U. S. A. 85:1988;5733-5737.
44. Ryan L.J., Clark K.B. Alterations of neuronal responses in the subthalamic nucleus following globus pallidus and neostriatal lesions in rats. Brain Res. Bull. 29:1992;319-327.
45. Sanberg P.R., Calderon S.F., Giordano M., Tew J.M., Norman A.B. The quinolinic acid model of Huntington's disease: locomotor abnormalities. Exp. Neurol. 105:1989;45-53.
46. Sapp E., Ge P., Aizawa H., Bird E., Penney J., Young A.B., Vonsattel J.P., DiFiglia M. Evidence for a preferential loss of enkephalin immunoreactivity in the external globus pallidus in low grade Huntington's disease using high resolution image analysis. Neuroscience. 64:1995;397-404.
47. Schwarcz B., Foster A.C., French E.D., Whetsell W.O., Köhler C. II. Excitotoxic models for neurodegenerative disorders. Life Sci. 35:1984;19-32.
48. Vonsattel J.P., DiFiglia M. Huntington disease. J. Neuropathol. Exp. Neurol. 57:1998;369-384.
49. Zadow B., Schmidt W.J. Lesions of the entopeduncular nucleus and subthalamic nucleus reduce dopamine receptor antagonist-induced catalepsy in rats. Behav. Brain Res. 62:1994;71-79.